Eugene Major Email and Phone Number

Q: What company does Eugene Major work for?

Eugene Major works for ImagineRx

Q: What is Eugene Major's email address?

Eugene Major's email address is eugene@dunbarcapital.com

Q: What is Eugene Major's direct phone number?

Eugene Major's direct phone number is +12128717100

Eugene Major's Location

New York, New York, United States, United States

Eugene Major's Contact Details

Eugene Major work email

eu****@****tal.com View
Valid
em****@****lth.com View
Valid

Eugene Major personal email

eu****@****ail.com View
Valid

Eugene Major phone numbers

About Eugene Major

CEO, CFO, senior executive and builder of growing companies in biotech/healthcare and other industries with extensive experience imposing financial discipline while bringing a high level of managerial expertise.Adept at partnering with outstanding entrepreneurs to build great companies, including successfully maneuvering the challenges of high growth and innovation, recruiting and retaining the best team, and building a fantastic work culture.Career Highlights● Managing Partner, CFO, founder, and builder of financial industry startup, Dunbar Capital, that grew to over $225 million in AUM successfully serving large corporate customers such as LPL, Lincoln Financial, MassMutual and AXA and several hundred clients in 30+ states. Developed, implemented, and led “best practice” institutional quality financial function/business controls, policies and procedures, compliance effort and investment process. ● Interim CFO - recruited to turn around a healthcare tech startup in financial crisis and quickly stabilized and rebuilt company’s financial function, restored confidence with key stakeholders and enabled company to raise $15 million to position it to return to growth mode.● Business lead for a Princeton University biotech venture, analyzed the commercializationpotential of insulin/synthetic protein design technology and raised funds to continue development of insulin in Princeton lab.● Portfolio manager - invested in thousands of public and private companies including distressed assets.● Investment banker - advised public and private companies undergoing complex financial restructurings, equity and debt offerings and M&A transactions. Areas of ExpertiseRaising Equity & Debt Capital | Business Development | Financial Planning & Analysis | Crisis Management | Financial Restructuring | Team Leadership | Growth Initiatives | Board Communication/Presentations | Budget Management | Revenue/Profit Growth | Strategic Partnerships | Business Planning | Risk Management | Utilizing Princeton/Columbia Alumni & Financial Industry Networks to Build Company | Passionate About Investor Relations & Customer Service | Recruiting of A Players | Identifying & Implementing Best practices | Managing Complex Tax, Regulatory & Accounting Issues | Articulate Oral and Written Communicator | Accurate Projections Models | Cash Management & Controls | Thinking Out of the Box | Solve Complex Problems With Imperfect/Noisy Data | Negotiate Complicated Agreements | Due DiligenceSwim More Than a Mile Daily | Community Volunteer

Eugene Major's Current Company Details

Imaginerx

View

Eugene Major Work Experience Details

Ceo And Co-Founder

Imaginerx Apr 2024 - Present

Working on commercializing a patented Memorial Sloan Kettering Technology that uses natural language processing combined with deep domain expertise to analyze electronic health records/real world data/real world evidence to provide actionable insights to benefit various healthcare industry stakeholders.Participated in May-August 2024 NSF I-Corps Cohort run by Rutgers University to conduct customer discovery interviews related to this technology.Attended 22nd International Conference on Artificial Intelligence in Medicine in Salt Lake City, Utah in July 2024 (https://aime24.aimedicine.info/).

View
Angel Investor/Wavelydx

Technology Startup Cfo/Business Builder/Entrepreneur Jun 2023 - Present

Invested in WavelyDx which builds phone-based tools to support pediatric care. Its first tool is a phone app that can detect fluid in the middle ear to help a doctor diagnose and treat ear infections remotely.
Angel Investor/Ceretype Neuromedicine

Technology Startup Cfo/Business Builder/Entrepreneur Jan 2022 - Present

Invested in Ceretype Neuromedicine which provides actionable individual and population insights through unparalleled, commercializable visibility into brain circuitry—offering precision to stakeholders across the global healthcare ecosystem. This solution will bring new therapeutics to the market faster and revolutionize the treatment of psychiatric and neurological disorders.
Angel Investor/Massive Bio

Technology Startup Cfo/Business Builder/Entrepreneur Nov 2020 - Present

Invested in Massive Bio, a leader in precision medicine and artificial intelligence enabled patient centric clinical trial enrollment. Massive Bio has a rapidly growing roster of clients across the pharmaceutical company and contract research organization industry globally.
Angel Investor/Neurorx

Technology Startup Cfo/Business Builder/Entrepreneur Jul 2020 - Present

Invested in NeuroRx, a biotechnology company founded by Princeton alumni. Company is developing a treatment for COVID-19-related Lung Injury and Acute Respiratory Failure (ARDS). Company has the first drug in development to treat bipolar depression in patients with acute suicidality. In May 2021, NeuroRx merged with a special purpose acquisition company (SPAC) and become a public Nasdaq-listed company (NRX Pharmaceuticals - NRXP).
Angel Investor/Glossgenius

Technology Startup Cfo/Business Builder/Entrepreneur Jul 2018 - Present

Invested in GlossGenius, a software platform for beauty professionals co-founded by a Princeton alumna, in 2018. Met with hundreds of potential technology startup investments in Princeton alumni universe, Columbia Business School alumni network and Israeli entrepreneurial ecosystem.
Member And Deal Lead/Princeton University Alumni Angels

Technology Startup Cfo/Business Builder/Entrepreneur Feb 2018 - Aug 2024

Princeton Alumni Angels is a platform where Princeton University alumni work together to due diligence and invest in startups connected to Princeton alumni.
Angel Investor/Goldilocks Therapeutics, Inc.

Technology Startup Cfo/Business Builder/Entrepreneur Apr 2021 - Aug 2022

Invested in Goldilocks, a Memorial Sloan Kettering Cancer Center biotechnology spinout company founded by a Princeton alumnus and an MSKCC research scientist who is an alumnus of Robert Langer's bioengineering lab at M.I.T. Company is developing a treatment of kidney diseases utilizing proprietary mesoscale nanoparticle (MNP) versions of novel and already approved drugs.
Economic Crisis Investor

Technology Startup Cfo/Business Builder/Entrepreneur Apr 2020 - Dec 2021

Evaluating potential investments in sectors impacted by current economic crisis including technology, healthcare, hospitality, fitness, real estate and energy among others. Made investment related to FED TALF 2020 program.
Interim Chief Financial Officer/Cecelia Health ("Ch") (Healthcare Startup With 200 Person Team)

Technology Startup Cfo/Business Builder/Entrepreneur Jul 2019 - Sep 2019

CH is a tech-enabled diabetes/chronic disease management company. Appointed by board to rebuild CH's finance function. Quickly stabilized situation so that CH could raise capital and regain confidence of key stakeholders. Put CH in position to focus on continued growth. Achievements included:-Quickly developed trust with CH team to analyze and get "buy-in" on new projections assumptions. -Aggressively managed cash by stretching out payables and monetizing/advancing receivables resulting in swing of $900,000 giving CH “breathing room” to raise capital.-Came up with creative financing options such as factoring and other alternatives.-Used FP&A experience to develop a highly accurate projections model that gave stakeholders confidence regarding CH’s cash situation. -Made significant changes to CH’s longer-term projections which helped CH analyze its capital needs.-Worked to repair CH’s bank relationship and get bank to come up with more attractive terms.-Helped CH avoid wasting significant money/time on a bank deal that had non-workable closing conditions by insightful analysis of complex term sheet.-Enabled CH to raise $2.35 million from existing investors in an orderly fashion.-Introduced CH to diabetes community angel investors who invested an additional $2.5 million in the short time window needed by CH. Investors then led $13mm round. -Provided value-added services to all areas of CH.-Successfully entered CH into Columbia alumni VC intro program (only 15% of entrants get introduction to major corporate VC).-Used extensive networks to quickly source and recruit a candidate for a position at CH that was hard to fill. -Evaluated CH’s cash/credit card controls. Made recommendations regarding controls of CH’s bank accounts & cash movement/vendor payment policies to protect against fraud and other risks. -Presented reports to Board that were comprehensive, thoughtful and easily understood.-Received equity bonus for outstanding contribution and effort.
Business Lead/Cfo/Synthetic Protein Design Technology Startup/Princeton University

Technology Startup Cfo/Business Builder/Entrepreneur Nov 2018 - Jun 2019

Led effort to assess commercialization potential of synthetic protein design technology created by Princeton academics. Found a non-traditional non-dilutive partner/investor to advance development of insulin towards the goal of getting it in the hands of diabetics who have difficulty obtaining insulin at a reasonable price. Key achievements included:-Despite no previous experience with diabetes, insulin or protein design technology, was able to speak with over 125 people involved in these areas within a short period of time and come up with a deep understanding of what the key business/investment issues were and what was doable. -Spoke with investors (professional and angel), potential customers/partners, regulatory experts, foundations, scientists, other companies in the space, consultants (FDA and others), lawyers, industry executives, people involved with drug platform companies that could be a model for this venture, insulin price activists, and academics. -Feedback was to pivot from insulin because neither professional investors nor diabetes community angel investors were interested in investing to compete with the three large insulin producers based on the price of biosimilar insulin. -Despite this feedback, found a funder who put up $160,000 to develop insulin and possibly fund an expensive FDA process to bring that insulin to patients. -As a backup plan, developed a crowdfunding effort for insulin project. -Despite significant uncertainty regarding other applications of the technology, found potential partners/customers who were interested in exploring the technology. -Analyzed a complicated VC equity funding offer and helped academics respond and negotiate term sheet. Through advice and finding of funding alternatives, helped academics avoid agreeing to deal that presented significant long term problems.-Provided significant value in complex situation. If not for Eugene's efforts, technology development might not be moving forward today.
Consultant/Wenspire (Cybersecurity Industry Startup)

Technology Startup Cfo/Business Builder/Entrepreneur Sep 2018 - Nov 2018

Introduced Wenspire to major potential U.S. customers - financial institutions and healthcare companies that have significant data that needs to be protected from cybersecurity threats. These potential customers included one of the largest global investment banks, one of the largest global commercial banks, and one of the largest healthcare insurance companies in the U.S.
Consultant/Segasec Ltd. (Cybersecurity Industry Startup)

Technology Startup Cfo/Business Builder/Entrepreneur Apr 2018 - Oct 2018

Introduced Segasec to major potential U.S. customers - financial institutions and healthcare companies that have significant data that needs to be protected from cybersecurity threats. These potential customers included one of the largest global investment banks, one of the largest Canadian banks, and a healthcare company.
Consultant/Raycatch, Ltd. (Solar Industry Startup)

Technology Startup Cfo/Business Builder/Entrepreneur Mar 2018 - Oct 2018

Introduced Raycatch to potential U.S. customers - owners of large commercial solar assets. These potential customers included one of the largest global investment banks, one of the largest global private equity firms and one of the largest global hedge funds. Introduced Raycatch to a major U.S. owner of commercial solar assets that became Raycatch's first U.S. pilot. Negotiated pilot agreement with this large financial institution.
Chief Executive Officer/Co-Founder

Columbia University Drug Delivery Technology - Glioblastoma Nov 2020 - Present

Columbia University spinout of drug delivery platform targeting diseases related to the brain.-First application hunts down glioblastoma (GBM) tumor cells and delivers anti-tumor drugs. -Technology comprises a mesenchymal stem cell (MSC) spheroid entrapping drug-loaded nanocomposite. The combination of MSC and nanoparticles enables this system to target GBM tumors with high cell retention and deliver combinations of payloads including proteins and therapeutic drugs. -GBM is the most common and aggressive form of brain cancer with no effective treatment options. -Co-founded company with Kam Leong who is the Samuel Y. Sheng Professor in the departments of biomedical engineering and systems biology at Colombia. Prof. Leong is an inventor behind Gliadel, the only FDA-approved drug delivery technology for GBM. Prof. Leong is a member of the National Academy of Medicine and the National Academy of Engineering and is a pioneer in developing multifunctional nanoscale technologies for delivering drugs, antigens, proteins, siRNA and DNA to cells.-Selected to participate in the inaugural 2021 cohort of the Columbia Venture Community Healthcare Initiative.-Selected to participate in Columbia University's Accelerating Cancer Therapeutics (ACT) Program 2021 Cohort.-Selected to participate in Westchester County Biosciences Accelerator 2021 Cohort (run by same team as ELabNYC Bio and Health Tech NYC accelerator).-Selected as a member of the UMass I-Corps@NCATS Fall 2021 Program (National Center for Advancing Translational Sciences)
Chief Executive Officer

Recurx Bio Jul 2023 - Feb 2024

RecurX Bio's phenotypic microfluidic assay captures the deadly cell sub-population responsible for cancer metastasis and rapid spread. The diagnostic test is used to determine how serious is the patient’s disease, reveal how well the standard of care treatment will work and uncover better existing drugs for personalized patient treatment. Johns Hopkins University I-Corps programDelaware Science Inc. AcceleratorBlueprint Engine AcceleratorJohns Hopkins University Intellectual Property
Founder, Managing Partner, Chief Investment Officer, And Cfo Of Sec Registered Fund Of Hedge Funds

Dunbar Capital/Financial Industry Startup Jul 1996 - Aug 2016

-Grew AUM from $1mm to $225mm with 100s of clients & multiple US/non-US investment entities.-Successfully navigated many market environments including 2008 crisis. Outperformed financial market and HF indices in 2008 and avoided leverage, frauds and other issues that hurt many funds.-Led monthly accounting/annual audit process for 20 years without any issues. Delivered timely/accurate monthly statements to 100s of clients and over 60 sets of audited financial statements.-Led financial planning & analysis (FP&A) to project expenses and manage cash/investments.-Produced over 35 complex tax returns and K-1s for 100s of clients for 20 years.-Created SEC compliance program. Successfully navigated a long routine SEC audit. Emphasis on strong “culture of compliance” & “best practices”.-Relationships with large financial advisor & insurance firms such as LPL, Lincoln Financial, MassMutual and AXA and their top advisors/clients. Passed rigorous due diligence. Institutional quality financial/business controls, policies and procedures.-Strong cybersecurity, disaster recovery, IT infrastructure and “best in class” cash/ bank account controls to prevent fraud.-Made 100s of investor presentations to larger/smaller groups.-Human resources process to source/ recruit top people, develop a strong culture to retain talent and manage 15 person team.-Deep networks (fellow CFOs, financial industry professionals, and Princeton and Columbia Business School alumni) which served as a resource for information, best practices, recruiting, contacts, and business development.-Wrote monthly investor letter for 20 years.-Led quarterly investor conference calls as part of “high touch customer/client service”.-Led investment/due diligence process of funds & their public/private investments. Led monthly investment committee process (like board of directors).-Negotiated 100s of legal agreements with funds, service providers, employees, and business partners.-Managed bank facility.
Founder, Portfolio Manager, And Cfo Of Financial Industry Startup

Lido Partners, L.P. - Long/Short Equity Hedge Fund 1994 - 2000

My first entrepreneurial start-up venture. Lido Partners was a long/short equity hedge fund which invested in equity, debt and other securities of public companies. Achievements included:-Managed an onshore fund, offshore fund and managed accounts.-Served as CFO - oversaw monthly accounting, annual audit and annual tax/K-1 process.-Led investment process and served as portfolio manager.-Conducted dozens of one-on-one due diligence meetings with CEOs and CFOs of public companies each year. Companies were actual and/or potential investments.-Attended dozens of "roadshow" meetings with public company management teams each year (IPOs, debt offerings, spin-offs and other transactions).-Key part of every investment analysis was projection of a company's future revenues, expenses, profits and cash flows.-Analyzed potential investments' strategic plan and business strategy.-In-depth analysis of financial statements and all public company SEC filings of potential investments.-Made numerous presentations to investors and potential investors.-Wrote monthly letter to investors.
Portfolio Manager - Long/Short Equity

Millennium Partners 1993 - 1994

Opportunity to serve as sole portfolio manager for the first time. Millennium Partners is a large multi-strategy hedge fund. Achievements included:-Managed a long/short portfolio which invested in equity, debt and other securities of public companies. -Led investment process and served as portfolio manager.-Conducted dozens of one-on-one due diligence meetings with CEOs and CFOs of public companies each year. Companies were actual and/or potential investments.-Attended dozens of "roadshow" meetings with public company management teams each year (IPOs, debt offerings, spin-offs and other transactions).-Key part of every investment analysis was projection of a company's future revenues, expenses, profits and cash flows.-In-depth analysis of financial statements and all public company SEC filings of potential investments.-Analyzed potential investments' strategic plan and business strategy.
Assistant Portfolio Manager - Distressed Securities

Odyssey Partners, L.P./Multi-Strategy Hedge Fund 1991 - 1993

Was hired away from Smith Barney. Odyssey Partners was one of the largest multi-strategy hedge funds at the time managed by famed investors Jack Nash and Leon Levy. Achievements included:-Assistant portfolio manager for portfolio of distressed securities (bank debt, subordinated debt, trade credit, preferred stock, common equity and other securities). -Was lead analyst for portfolio comprised of several dozen complex investments in companies undergoing financial restructurings both in and out of bankruptcy.-Conducted in-depth financial analysis as well as legal and other analysis connected to bankruptcy or potential bankruptcy process.-Conducted dozens of one-on-one due diligence meetings with CEOs and CFOs of public companies each year. Companies were actual and/or potential investments.-Attended dozens of "roadshow" meetings with public company management teams each year (emergence from bankruptcy, IPOs, debt offerings, spin-offs and other transactions).-Key part of every investment analysis was projection of a company's future revenues, expenses, profits and cash flows.-In-depth analysis of financial statements and all public company SEC filings of potential investments.-Analyzed potential investments' strategic plan and business strategy.
Smith, Barney, Harris & Upham

Associate - Financial Restructuring Group/Public Companies 1990 - 1991

Associate in pre-eminent financial restructuring group hired by Smith Barney (now part of Citi) after Drexel Burnham Lambert went bankrupt. -Represented public companies undergoing complex financial restructurings.-Intensive due diligence of client prospects.-Construction of detailed models of future income statements, balance sheets and cash flow statements of client's business. Projections had to be accepted by client and other creditors/stakeholders of the company.-Analyzed clients' strategic plan and business strategy.-Conducted valuation analysis of comparable companies to come up with company valuation to be used for negotiations among creditors/stakeholders.-In-depth analysis of financial statements and all public company SEC filings of clients and comparable companies.-Negotiation of complicated restructuring transactions between client and its creditors/stakeholders.-Negotiation of complex bank agreements, subordinated debt indentures, covenants and other agreements among multiple creditor classes and numerous investors in the securities of those classes.-Pitched group's services to potential clients.-Advised clients on "roadshow" presentations to creditors/stakeholders. -Received outstanding annual reviews.
Drexel Burnham Lambert/Pioneer Of The High Yield Bond Market

Associate - Financial Restructuring Group/Public Companies 1988 - 1990

First job after completion of MBA. Associate in investment banking department at firm that pioneered the high yield bond market. -Financial restructuring transactions as described under Smith Barney above.-Also provided advice to public companies involved in initial public offerings of equity, high yield bond offerings, and mergers and acquisitions.-Intensive due diligence of client prospects.-Construction of detailed models of future income statements, balance sheets and cash flow statements of client's business. Projections had to be accepted by investment banking clients and other parties involved in the transaction.-Analyzed clients' strategic plan and business strategy.-Conducted valuation analysis of comparable companies to come up with company valuation to be used for pricing investment banking transactions.-In-depth analysis of financial statements and all public company SEC filings of clients and comparable companies.-Negotiation of complicated transactions between client and its creditors/stakeholders.-Negotiation of complex bank agreements, subordinated debt indentures, covenants and other agreements among multiple creditor classes and numerous investors in the securities of those classes.-Pitched firm's services to potential clients.-Advised clients on "roadshow" presentations to creditors/stakeholders. -Received outstanding annual reviews.
Associate - Private Equity, Merger Arbitrage Analysis

Jamie Securities/Leading Merger Arbitrage Firm 1986 - 1988

Was hired away from Dean Witter Reynolds. Jamie Securities was one of the leading merger arbitrage firms at the time and one of the largest early hedge funds. Achievements included:-Analyzed private equity transactions and merger arbitrage investments.-Was analyst for portfolio comprised of several dozen companies undergoing complex merger/acquisition and/or financial restructuring transactions.-Had to analyze the business, financial, legal and strategic aspects of the companies involved in these merger transactions.-Conducted in-depth financial analysis as well as legal and other analysis connected to merger and/or financial restructuring process.-Analyzed potential private equity transactions to be acquired with firm capital.-Conducted dozens of one-on-one due diligence meetings with CEOs and CFOs and other executives of private equity targets.-Attended dozens of "roadshow" meetings with public company management teams each year.-Key part of every investment analysis was projection of a company's future revenues, expenses, profits and cash flows.-In-depth analysis of financial statements and all public company SEC filings of potential investments.-Analyzed potential investments' strategic plan and business strategy.-Received outstanding annual reviews.
Investment Banking Analyst - Mergers And Acquistions Group

Dean Witter Reynolds (Now Part Of Morgan Stanley) 1985 - 1986

First job after college graduation. Dean Witter was one of the largest brokerage firms at the time (now part of Morgan Stanley). Achievements included:-Provided advice to public and private companies undergoing merger and/or leveraged buyout transactions.-Intensive due diligence of client prospects.-Construction of detailed models of future income statements, balance sheets and cash flow statements of client' business. Projections had to be accepted by investment banking clients and other parties involved in the transaction.-Analyzed clients' strategic plan and business strategy.-Conducted valuation analysis of comparable companies to come up with company valuation to be used for pricing investment banking transactions.-In-depth analysis of financial statements and all public company SEC filings of clients and comparable companies.-Negotiation of complicated transactions between client and its creditors/stakeholders.-Negotiation of complex bank agreements, subordinated debt indentures, covenants and other agreements among multiple creditor classes and numerous investors in the securities of those classes.-Pitched firm's services to potential clients.-Advised clients on "roadshow" presentations to creditors/stakeholders. -Received outstanding annual reviews.
Summer Analyst/Part-Time Analyst

Oppenheimer & Co. Inc. Jun 1984 - May 1985

New York, Ny, Us

Worked with Institutional Investor All-America specialty chemicals analyst, Charlie Rose, in equity research department while a student at Princeton.-Analyzed universe of public specialty chemicals companies for the purpose of investment recommendations to institutional investors.-Had to analyze the business, financial, legal and strategic aspects of the companies in this universe.-Conducted in-depth financial analysis as well as legal and other analysis connected to companies involved in transactions such as mergers or hostile proxy fights.-Participated in one-on-one due diligence meetings with CEOs and CFOs of specialty chemicals companies.-Attended "roadshow" meetings with public company management teams.-Key part of every investment analysis was projection of a company's future revenues, expenses, profits and cash flows.-In-depth analysis of financial statements and all public company SEC filings of potential investments.-Analyzed potential investments' strategic plan and business strategy.-Received outstanding review.

View

Eugene Major Skills

Founder And Senior Executive Of Startup Business Development Professional Investor Leadership Strategic Planning Start Ups Business Strategy Marketing Sales Investments Finance Due Diligence Marketing Strategy Venture Capital Hedge Funds Private Equity Investment Banking Restructuring Asset Management Portfolio Management Mergers And Acquisitions Financial Modeling Strategy Securities Valuation Corporate Finance Equities Alternative Investments Financial Analysis Capital Markets Customer Relationship Management Financial Reporting Investor Relations Cash Management Disaster Recovery Recruiting Tax Accounting Budgeting Executive Management Strategic Partnerships Public Speaking Management Chief Financial Officer Chief Operating Officer Legal Angel Investing Ipo Capital Raising High Yield

Eugene Major Education Details

Princeton University

Aerospace Engineering
Columbia Business School

Finance
Ramaz School
Yeshivat Har Etzion

Frequently Asked Questions about Eugene Major

What company does Eugene Major work for?

Eugene Major works for Imaginerx

What is Eugene Major's role at the current company?

What is Eugene Major's email address?

Eugene Major's email address is eu****@****tal.com

What is Eugene Major's direct phone number?

Eugene Major's direct phone number is +121287*****

What schools did Eugene Major attend?

Eugene Major attended Princeton University, Columbia Business School, Ramaz School, Yeshivat Har Etzion.

What skills is Eugene Major known for?

Eugene Major has skills like Founder And Senior Executive Of Startup, Business Development, Professional Investor, Leadership, Strategic Planning, Start Ups, Business Strategy, Marketing, Sales, Investments, Finance, Due Diligence.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.

Security Check